|
In January 2008, the European Commission launched a sector inquiry into EU pharmaceuticals markets under the EC competition rules because information relating to innovative and generic medicines suggested that competition may be restricted or distorted. The motivating force behind the inquiry is the Commission’s perception that there is a decline in innovation in the sector when measured by the number of novel medicines reaching the market, and (not necessarily connected) that there are instances of delayed market entry of generic medicines as compared to what might be expected. |
